Financial Summary (All financials)
In millions, except per share items | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 |
Revenues | 20,997.0 | 19,635.0 | 18,749.0 | 9,231.0 | 10,986.0 | 11,420.0 | 13,107.0 | 13,154.0 |
Revenue growth | 6.9% | 4.7% | 103.1% | -16.0% | -3.8% | -12.9% | -0.4% | -1.8% |
Cost of goods sold | -9,138.0 | -8,542.0 | -8,252.0 | 8,369.0 | 9,974.0 | 10,303.0 | 11,799.0 | 11,713.0 |
Gross profit | 30,135.0 | 28,177.0 | 27,001.0 | 862.0 | 1,012.0 | 1,117.0 | 1,308.0 | 1,441.0 |
Gross margin | 143.5% | 143.5% | 144.0% | 9.3% | 9.2% | 9.8% | 10.0% | 11.0% |
Selling, general and administrative | | | | 313.0 | 360.0 | 0.0 | 0.0 | 43.0 |
Research and development | | | | | | | | |
General and administrative | 1,601.0 | 1,520.0 | 1,287.0 | | | 0.0 | 0.0 | |
EBITA | 1,211.0 | 1,074.0 | 991.0 | 894.0 | 1,051.0 | 1,160.0 | 1,366.0 | 1,504.0 |
EBITA margin | 5.8% | 5.5% | 5.3% | 9.7% | 9.6% | 10.2% | 10.4% | 11.4% |
Amortization of intangibles | 49.0 | 43.0 | 33.0 | 32.0 | 39.0 | 43.0 | 58.0 | 63.0 |
EBIT | 1,162.0 | 1,031.0 | 958.0 | 862.0 | 1,012.0 | 1,117.0 | 1,308.0 | 1,441.0 |
EBIT margin | 5.5% | 5.3% | 5.1% | 9.3% | 9.2% | 9.8% | 10.0% | 11.0% |
Pre-tax income | 924.0 | 871.0 | 804.0 | 639.0 | 872.0 | 980.0 | 1,122.0 | 1,162.0 |
Income taxes | 103.0 | 102.0 | 171.0 | 132.0 | 227.0 | 264.0 | 360.0 | 296.0 |
Tax rate | 11.1% | 11.7% | 21.3% | 20.7% | 26.0% | 26.9% | 32.1% | 25.5% |
Earnings from continuing ops | 821.0 | 1,538.0 | 633.0 | 1,014.0 | 645.0 | 716.0 | 752.0 | 852.0 |
Earnings from discontinued ops | 205.0 | -76.0 | 91.0 | -732.0 | 32.0 | 44.0 | 32.0 | 104.0 |
Net income | 1,026.0 | 1,462.0 | 724.0 | 282.0 | 677.0 | 760.0 | 784.0 | 956.0 |
Net margin | 4.9% | 7.4% | 3.9% | 3.1% | 6.2% | 6.7% | 6.0% | 7.3% |
|
Diluted EPS | $10.31 | $19.32 | $8.03 | $12.38 | $7.35 | $7.86 | $7.70 | $8.07 |
Shares outstanding (diluted) | 79.6 | 79.6 | 78.8 | 81.9 | 87.8 | 91.1 | 97.6 | 105.6 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|